A Service For Professionals Wednesday, November 22, 2017
Contact (202) 540-8337
Company News Today
A Service For Professionals Wednesday, November 22, 2017 11614 Sources 417,032,608 Articles 3,022,490 Readers
Contact (202) 540-8337

Global ADME (Absorption, Distribution, Metabolism And Elimination) Toxicology Testing Market 2013 to 2022

/EIN News/ -- Dublin, April 27, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global ADME (Absorption, Distribution, Metabolism And Elimination) Toxicology Testing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2013 to 2022" report to their offering.

The ADME toxicology testing was valued at USD 6,986.2 Mn in 2015, and is expected to reach USD 14,319.9 Mn by 2022, expanding at a CAGR of 10.6% from 2016 to 2022.

ADME is the abbreviation for absorption distribution, metabolism and elimination, a pharmacology and pharmacokinetics term that describes the disposition of a drug or compound inside the human body. ADME comprises set of four processes that develop the performance of a drug on human tissue and ADME toxicology testing is applied for the development of a new drug. ADME toxicology facilitated pharmaceutical manufacturing company to minimize their drug discovery time, testing complications, and to reduce the cost of drug development. The growing application of ADME toxicology testing by pharmaceuticals and biotechnology companies is assisting the market growth of the ADME toxicology testing market.

One of the key factors responsible for late stage drug failures is the inability of drug candidates to imitate in humans the safety profile witnessed in animal models. Before introduction and acceptance of ADME toxicology testing, drug development process included toxicity and efficacy testing in in-vivo environment which was responsible for late stage failure of drugs in human body due to anatomical and genetic differences between animals and humans. To overcome this barrier of drug failure manufacturers across the globe opted for ADME toxicity testing in early drug developmental phases of pre-clinical trials. Increasing adoption of ADME toxicity testing as cost and time curbing tool is further expected to drive growth of this market. Introduction of technologically advanced computer based testing models are additionally fuelling growth of this market.

According to market stakeholders, recently pre-clinical ADME toxicology testing is emerging to take on a new application in the drug-discovery venture capital (VC) industry's financial decision that corresponds in importance and scope to its established role in the scientific decisions of drug discovery firms.

Key Market Movements:

  • Rising application of ADME toxicology testing by pharmaceuticals and biotechnology companies
  • Growing concerns over application of animals in clinical trials
  • Increase in demand of cell-based assays in drug discovery
  • Escalating adoption of ADME toxicity testing as cost and time curbing tool

The key players in this market are

  • Cellartis AB
  • Thermo Fisher Scientific, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Caliper Life Sciences, Inc.
  • Promega Corporation
  • Beckman Coulter, Inc.
  • Optivia Biotechnology, Inc.
  • Cyprotex PLC
  • Molecular Discovery Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/lj65x5/global_adme


                    
                    
                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716
                             Related Topics: Drug Discovery
                    

Primary Logo

Powered by EIN News